Quiz: Which Germline Mutations Are Linked to Ovarian Cancer?

Article

How much do you know about the link between various germline mutations and ovarian cancer? Take our latest quiz to test your knowledge.

In our June ovarian cancer quiz, you'll get a chance to test your knowledge of the incidence of various germline mutations and their associated risk of ovarian cancer. Here's your first question:
 

1. According to a 2019 meta-analysis, germline mutations in which of the following loci are associated with increased ovarian cancer risk but not increased breast cancer risk?

A.RAD51C

B.RAD51D

C.NBN

D.All of the above


Recent Videos
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
The Foundation for Women’s Cancer provides multicultural resources for patients with gynecologic cancers to help address gaps in care.
Ginger J. Gardner, MD, FACOG, addresses the growing uterine cancer cases among patients in the United States and the need for greater genetic testing.
Ginger J. Gardner, MD, FACOG, discussed the state of gynecologic cancers and her role in empowering research, education, and awareness surrounding them.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Related Content
Niraparib/Dostarlimab/Chemo Improves PFS Vs SOC in Advanced Ovarian Cancer

Niraparib/Dostarlimab/Chemo Improves PFS Vs SOC in Advanced Ovarian Cancer

Tim Cortese
December 20th 2024
Article

Niraparib/dostarlimab with platinum-therapy met its PFS end point in patients with advanced ovarian cancer in the phase 3 FIRST-ENGOT-OV44 trial.

Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.

Uterine Transposition May Maintain Fertility Following Pelvic Radiotherapy

John Paul Diaz, MD
November 4th 2024
Podcast

Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.

Barriers and gaps in treatment and care for patients diagnosed with gynecologic cancers were reported in a recent survey.

Survey Says Gaps Exist in Gynecologic Cancer Treatment

Tim Cortese
November 15th 2024
Article

Barriers and gaps in treatment and care for patients diagnosed with gynecologic cancers were reported in a recent survey.

Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.

Empowering Awareness to Address Rising Gynecological Cancer Incidence

Ginger J. Gardner, MD, FACOG
October 28th 2024
Podcast

Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.

An FDA filing decision is anticipated before the end of 2024 for avutometinib/defactinib in recurrent KRAS-mutant low-grade serous ovarian cancer.

Rolling NDA Completed for Avutometinib Combo in Ovarian Cancer Subtype

Russ Conroy
November 1st 2024
Article

An FDA filing decision is anticipated before the end of 2024 for avutometinib/defactinib in recurrent KRAS-mutant low-grade serous ovarian cancer.

Data from KEYNOTE-868 and KEYNOTE-A18 support the approval of pembrolizumab-based therapy in endometrial and cervical cancer, respectively.

Pembrolizumab Regimens Earn European Approvals in Gynecologic Cancers

Russ Conroy
October 24th 2024
Article

Data from KEYNOTE-868 and KEYNOTE-A18 support the approval of pembrolizumab-based therapy in endometrial and cervical cancer, respectively.